<!doctype html>
<html lang="en" manifest="cache.manifest">
  <head>
    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-E7V5SQE1XT"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-E7V5SQE1XT');
    </script>
    
    <link rel="manifest" href="manifest.json">
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

    <!-- Bootstrap CSS -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@100;200;300;400;500;600;700;800;900&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/style.css">

    <title>Agios</title>
  </head>
  <body>
    <nav class="navbar navbar-expand-lg navbar-dark">
      <div class="container">
        <a class="navbar-brand" href="index.html">
          <img src="images/logo.png" />
        </a>

        <ul class="navbar-nav ml-auto">
            <li class="nav-item active">
              <a class="nav-link" href="index.html">
                <img src="images/icons/home-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="peak-registry.html">
                <img src="images/icons/peak-registry-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="pkr-activator-pipeline.html">
                <img src="images/icons/pipeline-icon.png" width="30">
              </a>
            </li>
          </ul>
      </div>
    </nav>
    <main class="pipeline-details">
      <div class="container">
        <div class="row">
          <div class="col-sm-9 col-7">
            <h1 class="mb-4"><img class="riseup" src="images/rise-up.png"> Sickle Cell Disease Phase 2/3 Study Design</h1>
          </div>
          <div class="col-sm-3 col-5">
            <span class="badge blue-dark float-right mt-1">STATUS: INITIATING</span>
          </div>

          <div class="col-md-8">
            <h4 class="font-weight-normal mb-3">A phase 2/3, double-blind, randomized, placebo-controlled, multicenter study evaluating the safety and efficacy of mitapivat in patients with sickle cell disease (SCD)</h4>
          </div>
          <div class="col-md-12">
            <div class="block">
              <div class="row">
                <div class="col-md-12">
                  <img src="images/rise-up-phase-2.png" class="mb-0" />
                </div>
              </div>
            </div>

            <div class="block p-0">
                <div class="row">
                  <div class="col-md-6 pr-md-0">
                    <div class="p-30">
                      <p class="mb-1"><strong>Key Inclusion Criteria</strong></p>
                      <ul class="mb-0 pl-20">
                          <li>≥ 16 years of age; subjects who are 16 or 17 years of age must be documented Tanner Stage 5</li>
                          <li>Documented SCD (HbSS, HbSC, HbSβ0/HbSβ+ thalassemia, other SCD variants)</li>
                          <li>Recurrent vaso-occlusive crises (VOCs) – defined as the occurrence of 2–10 sickle cell pain crises (SCPCs; acute pain needing medical contact, acute chest syndrome, priapism, hepatic or splenic sequestration) in the prior 12 months</li>
                          <li>Anemia – defined as a Hb level of 5.5–10.5 g/dL</li>
                          <li>If taking hydroxyurea (HU), the dose must be stable for ≥ 90 days before starting study drug</li>
                      </ul>
                    </div>
                  </div>
                  <div class="col-md-6 pl-md-0 d-flex">
                    <div class="p-30 side-block-gray w-100">
                      <p class="mb-1"><strong>Key Exclusion Criteria</strong></p>
                      <ul class="mb-0 pl-20">
                          <li>Receiving regularly scheduled red blood cell transfusions</li>
                          <li>Severe kidney disease or hepatobiliary disorders</li>
                          <li>Currently receiving treatment with SCD therapies (excluding HU)</li>
                          <li>Prior exposure to gene therapy, or prior bone marrow or stem cell transplantation</li>
                      </ul>
                    </div>
                  </div>
                </div>
              </div>
          </div>
          <div class="col-md-12 text-right mb-3">
            <a class="btn btn-outline-primary" href="phase-2-3-rise-up-endpoints.html">ENDPOINTS <img src="images/icons/arrow-right.png"></a>
          </div>
        </div>
        <footer>
            <div class="row">
              <div class="col-md-6">
                <p class="text-left">
                <sup>a</sup>Patients who receive mitapivat in the double-blind period will continue to receive the same dose of mitapivat in the open-label extension period, patients who receive placebo will be randomized 1:1 to mitapivat 50 mg BID or 100 mg BID; <sup>b</sup>Randomization stratification factors: Number of SCPCs in the prior year (< 5, ≥ 5), hydroxyurea use (yes, no).<br/>
                BID = twice daily; Hb = hemoglobin; SCD = sickle cell disease; SCPC = sickle cell pain crises; wks = weeks.</p>
              </div>
              <div class="col-md-6">
                <p class="text-right">For additional details, search ClinicalTrials.gov for<br/>
                  NCT05031780 or EudraCT for 2021-001674-34.<br/>
                  For more information (physician/HCP only),<br/> 
                  please email medinfo@agios.com.<br/>
                &copy;2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
              </div>
            </div>
        </footer>
      </div>
    </main>
    <div class="screensaverDiv d-none">
      <img src="images/screensaver.gif" class="screensaverImg" />
    </div>

    <!-- Optional JavaScript -->
    <!-- jQuery first, then Popper.js, then Bootstrap JS -->
    <!-- <script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.9/umd/popper.min.js" integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q" crossorigin="anonymous"></script> -->
    <script src="js/jquery-3.4.1.min.js"></script>
    <script src="js/bootstrap.min.js"></script>
    <script src="js/screensaver.js"></script>
  </body>
</html>